Immatics (IMTX) Debt Ratio (2020 - 2022)

Immatics recorded quarterly Debt Ratio of 0.06 in Q3 2022, up 47.15% quarter-over-quarter from 0.04 in Q2 2022, and down 57.27% year-over-year from 0.13 in Q3 2021.

Immatics' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.06 for Q3 2022.

  • In Q3 2022, Debt Ratio fell 57.27% year-over-year to 0.06; the TTM figure through Sep 2022 stood at 0.06 (down 57.27% YoY), while the FY2021 annual figure was 0.16, up 140.8% from the prior year.
  • Debt Ratio came in at 0.06 for Q3 2022 at Immatics, up from 0.04 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.16 in Q4 2021 to a low of 0.04 in Q2 2022.
  • A 3-year average of 0.08 and a median of 0.07 in 2020 frame the typical range for Debt Ratio.
  • Across the five-year window, Debt Ratio jumped 140.8% in 2021 and tumbled 60.11% in 2022, its largest moves.
  • Immatics' Debt Ratio stood at 0.07 in 2020, then surged by 140.8% to 0.16 in 2021, then slumped by 64.64% to 0.06 in 2022.
  • According to Business Quant data, Debt Ratio over the past three periods registered 0.06, 0.04, and 0.04 for Q3 2022, Q2 2022, and Q1 2022 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 1.41
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Immatics 1.80 Bn 1.80 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2022 0.06
Jun 30, 2022 0.04
Mar 31, 2022 0.04
Dec 31, 2021 0.16
Sep 30, 2021 0.13
Jun 30, 2021 0.10
Mar 31, 2021 0.08
Dec 31, 2020 0.07